NY-DILIGENT
28.9.2021 15:03:12 CEST | Business Wire | Press release
Diligent Corporation , the global leader in SaaS governance, risk and compliance (GRC) today announces that Ricardo Moreno has joined the company as the new Senior Vice President of Worldwide Partnerships and will also lead commercial growth for Latin America.
In the newly created role, Moreno will develop and execute a global strategy to drive new revenue streams for Diligent through go-to-market and technology partnerships and expand resources, enablement and incentives to maximize the mutual value of partnerships. In addition, he will be responsible for driving revenue generation and business development as Chief Revenue Officer of Latin America for the company.
“Our governance, risk and compliance software—and our new ESG solution—are a natural fit for the partner ecosystem,” said Lisa Edwards, Diligent’s COO. “This new role reflects Diligent’s increased focus on resellers, systems integrators, and strategic partnerships to enhance our customers’ GRC effectiveness. Ricardo brings extensive business development expertise to Diligent, and will contribute to the acceleration of our global footprint by maximizing the value of partnerships for the company, and growing our presence in Latin America.”
A seasoned partnership executive with roots in Latin America and deep global experience, Moreno joins Diligent from Zendesk, where he built the worldwide partner business that helped the company grow to over $1 billion in revenue. Previously, Moreno led multi-billion dollar partner sales businesses as GM and VP for Global Partner Sales at Intel and as Cisco's Vice President for the US and LATAM partner organization.
“As the leading governance, risk and compliance provider, Diligent is on an exciting growth trajectory, and this role emphasizes the company's increased commitment to leveraging partnerships to deepen its impact and meet the needs of customers,” said Ricardo Moreno. “I look forward to expanding Diligent's partnerships program and increasing market share in Latin America.”
About Diligent
Diligent is the leading governance, risk and compliance (GRC) SaaS company, serving more than one million users from over 25,000 organizations around the globe. Our modern GRC platform ensures boards, executives and other leaders have a holistic, integrated view of ESG data, audit, risk, information security, ethics and compliance across the organization. Diligent brings technology, insights and confidence to leaders so they can build more effective, equitable and successful organizations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210928005612/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting21.4.2026 16:00:00 CEST | Press release
- Data from pivotal frontMIND study of tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) featured in oral presentation at ASCO; results support global regulatory submissions Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi®/Minjuvi®) in first-line diffuse large b-cell lymphoma (DLBCL) will be featured as an oral presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held May 29 – June 2, 2026, in Chicago. “The positive Phase 3 frontMIND results for tafasitamab in patients with newly diagnosed diffuse large B-cell lymphoma highlight Incyte’s continued focus on advancing novel differentiated approaches with the potential to meaningfully impact patients,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “We look forward to sharing the full data at ASCO, and to progressing our pipeline.” Presentation details:
Wolters Kluwer CCH Tagetik Kicks Off Global inTouch 2026 Series Showcasing Expert AI in Action for the Office of CFO21.4.2026 15:28:00 CEST | Press release
Wolters Kluwer CCH Tagetik is set to host Global inTouch 2026, its flagship user conference which takes place May 19–21, 2026, in Lucca, Italy. Celebrating its 20th edition, Global inTouch launches a global event series demonstrating how CCH Tagetik with Expert AI is transforming the way finance works with AI-enabled capabilities embedded directly into the processes that matter most to the office of the CFO. Following the event in Lucca, the Global inTouch showcase will continue with regional inTouch events across key markets worldwide, including Belgium, France, Germany, Japan, the Netherlands, Sweden, the United Kingdom, and the United States. This year’s theme, Own the Future, reflects Wolters Kluwer CCH Tagetik’s commitment to continuous innovation and to empowering finance teams to deliver impact today while confidently shaping what’s next. “The role of the CFO is expanding from reporting on the past to strategically orchestrating the future to maximize value creation,” saidMaria
Wasabi Technologies Closes $250M Credit Facility to Expand Cloud Storage Innovation21.4.2026 15:00:00 CEST | Press release
Bain Capital;U.S. Private Credit Investments, a division of BTG Pactual Global Alternatives; Neuberger Specialty Finance; Energy Impact Partners; and Aksia continue to back storage infrastructure for the AI era Wasabi Technologies, the hot cloud storage company, today announced it has secured a $250 million credit facility led by Bain Capital’s Private Credit Group (“Bain Capital”) with participation from U.S. Private Credit Investments, a division of BTG Pactual Global Alternatives; Neuberger Specialty Finance; Energy Impact Partners; and Aksia. The financing will support continued investment in Wasabi’s cloud storage platform, infrastructure, and broader global expansion. “This is a more selective private lending market, but we’ve built a strong, disciplined business that continues to attract support from leading financial institutions,” said Michael Bayer, EVP and chief financial officer, Wasabi Technologies. “We’re investing in our infrastructure to meet growing demand for data, es
Aga Khan Museum Launches Season 5 of This Being Human as a Multimedia Video Podcast with new host, Mai Habib21.4.2026 15:00:00 CEST | Press release
The newest season of This Being Human explores art and culture, identity, and shared values through global conversations with artists and cultural thinkers The highly anticipated launch of Season 5 of This Being Human marks a dynamic new chapter for the Aga Khan Museum’s acclaimed podcast, expanding both its reach and storytelling. Now hosted by former journalist and cultural advocate Mai Habib, the new season brings listeners into compelling dialogue with artists and thought leaders whose work offers a global perspective on art and culture, identity, and new and pressing ideas that shape humanity today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421929514/en/ This Being Human Podcast Logo, Courtesy of the Aga Khan Museum Building on an impressive footprint of more than 100 episodes over the past four seasons, This Being Human will evolve into an audiovisual experience for the first time. Each of the 12 episodes will
Crown Bioscience and Turbine Partner to Connect AI-Driven Prediction with Organoid Validation in Translational Oncology21.4.2026 14:30:00 CEST | Press release
Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, today announced a strategic partnership with Turbine, a leading virtual biology company, to advance translational oncology research by integrating Turbine’s in silico Virtual Assays with its Tumor Organoid Assays based on HUB Organoid Technology. This collaboration establishes a connected workflow that enables researchers to move more efficiently from hypothesis to validation. Turbine’s Virtual Assays simulate biological response across thousands of biological samples and hundreds of drugs, generating predictive insights to identify and prioritize targets, therapies, and combinations. The predictions will be enhanced through the incorporation of multimodal and drug response data from hundreds of tumor organoid models at Crown Bioscience. Together, the companies create a closed-loop approach linking prediction with validation, improving predictive accuracy, reducing experimental burden, whil
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom